Quantification of muscle pathology in infantile Pompe disease

Neuromuscul Disord. 2017 Feb;27(2):141-152. doi: 10.1016/j.nmd.2016.10.010. Epub 2016 Nov 3.

Abstract

The effects of enzyme replacement therapy (ERT) in infantile Pompe disease are variable, necessitating the identification of biomarkers to assess the severity of disease and response to ERT. The aims of this study were to investigate whether quantification of muscle pathology in infantile Pompe disease prior to and during ERT is feasible at the light microscope, and to develop a score that summarizes the degree of muscle pathology in a comprehensive manner from PAS-stained resin sections alone. We, therefore, determined glycogen load, extent of muscle fibre disruption, and amount of autophagic vacuoles in resin-embedded muscle biopsy specimens from 11 infantile Pompe patients and 2 with early childhood phenotype by quantitative methods, correlated the findings with ultrastructural analyses, compared PAS-stained resin sections with conventional PAS-stained cryosections, and related the quantified degree of muscle damage from infantile patients to the effects of ERT. Comparison of electron and light microscopic findings demonstrated that important alterations of skeletal muscle morphology can also be depicted by examining PAS stained resin sections. Infantile patients with good response to ERT had lower muscle pathology score values prior to and during ERT than those with moderate and poor response, but the number of tissue samples available for evaluation was limited. These findings suggest that quantification of muscle pathology by analysing PAS stained resin sections is in principle feasible and useful to monitor disease progression and therapy response. These results have to be validated by investigating a larger group of patients.

Keywords: Acid maltase deficiency; Autophagy; Enzyme replacement therapy; Glycogen storage disease type II; Lysosomal storage disease; Pompe disease.

MeSH terms

  • Age of Onset
  • Child
  • Child, Preschool
  • Enzyme Replacement Therapy
  • Female
  • Glycogen Storage Disease Type II / drug therapy
  • Glycogen Storage Disease Type II / pathology*
  • Glycogen Storage Disease Type II / physiopathology
  • Humans
  • Infant
  • Male
  • Muscle, Skeletal / pathology*
  • Muscle, Skeletal / ultrastructure
  • Severity of Illness Index*
  • alpha-Glucosidases / administration & dosage
  • alpha-Glucosidases / pharmacology*

Substances

  • GAA protein, human
  • alpha-Glucosidases